FDA Approves BRIMONIDINE TARTRATE — Apotex Corp.

# FDA Approves Apotex's Generic Brimonidine Tartrate Ophthalmic Treatment Apotex Corp. received FDA approval for its generic brimonidine tartrate ophthalmic formulation, expanding the competitive landscape for alpha-2 adrenergic agonist treatments and potentially lowering costs for patients managing glaucoma and ocular hypertension. The approval could capture additional market share in the generic ophthalmology segment as healthcare providers shift to more cost-effective alternatives.